Maria Badillo

2.0k total citations
16 papers, 163 citations indexed

About

Maria Badillo is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Maria Badillo has authored 16 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 11 papers in Genetics and 7 papers in Oncology. Recurrent topics in Maria Badillo's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Gastrointestinal Tumor Research and Treatment (4 papers). Maria Badillo is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Gastrointestinal Tumor Research and Treatment (4 papers). Maria Badillo collaborates with scholars based in United States and China. Maria Badillo's co-authors include Michael Wang, Jorge Romaguera, Felipe Samaniego, Liang Zhang, Jason R. Westin, Hun Ju Lee, Preetesh Jain, Luis Fayad, Nathan Fowler and Rashmi Kanagal‐Shamanna and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Maria Badillo

16 papers receiving 163 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Badillo United States 6 99 92 81 29 20 16 163
Reiko Seki Japan 5 28 0.3× 95 1.0× 41 0.5× 5 0.2× 25 171
Namrata Shah United States 6 49 0.5× 68 0.7× 36 0.4× 2 0.1× 4 0.2× 15 114
Sang T. Kim United States 8 132 1.3× 16 0.2× 27 0.3× 5 0.2× 12 195
Outi Varpuluoma Finland 5 13 0.1× 159 1.7× 131 1.6× 9 0.3× 11 189
Federica De Marco Italy 4 34 0.3× 47 0.5× 23 0.3× 16 0.6× 1 0.1× 6 158
Donne Bennett Caces United States 7 60 0.6× 59 0.6× 29 0.4× 3 0.1× 1 0.1× 9 114
Hui Xiong China 7 49 0.5× 63 0.7× 11 0.1× 12 0.6× 17 134
Yue Ren China 7 126 1.3× 28 0.3× 7 0.1× 6 0.2× 4 0.2× 16 180
Cristina Bozzao Italy 8 46 0.5× 51 0.6× 9 0.1× 2 0.1× 4 0.2× 10 176
Abderrazak El Yamani France 4 36 0.4× 43 0.5× 28 0.3× 12 0.4× 6 55

Countries citing papers authored by Maria Badillo

Since Specialization
Citations

This map shows the geographic impact of Maria Badillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Badillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Badillo more than expected).

Fields of papers citing papers by Maria Badillo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Badillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Badillo. The network helps show where Maria Badillo may publish in the future.

Co-authorship network of co-authors of Maria Badillo

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Badillo. A scholar is included among the top collaborators of Maria Badillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Badillo. Maria Badillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Shaojun Zhang, et al.. (2021). Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology. 96(5). E137–E140. 5 indexed citations
3.
Badillo, Maria, et al.. (2020). Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. Clinical journal of oncology nursing. 24(4). 392–398. 4 indexed citations
4.
Lee, Hun Ju, et al.. (2020). A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma. British Journal of Haematology. 188(6). e94–e98. 4 indexed citations
5.
6.
Nomie, Krystle, Nikita Kotlov, Viktor Svekolkin, et al.. (2019). Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma. Blood. 134(Supplement_1). 2762–2762. 1 indexed citations
7.
Ning, Matthew S., Chelsea C. Pinnix, Bhavana V. Chapman, et al.. (2019). Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Advances. 3(13). 2035–2039. 11 indexed citations
8.
Jain, Preetesh, Jorge Romaguera, Hun Ju Lee, et al.. (2018). Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). British Journal of Haematology. 182(3). 404–411. 46 indexed citations
9.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Shaojun Zhang, et al.. (2018). Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood. 132(Supplement 1). 4151–4151. 5 indexed citations
10.
Badillo, Maria, et al.. (2015). Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. Journal of the Advanced Practitioner in Oncology. 6(5). 420–31. 8 indexed citations
11.
Wang, Yucai, Shouhao Zhou, Maria Badillo, et al.. (2015). Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial.. Journal of Clinical Oncology. 33(15_suppl). 8542–8542. 1 indexed citations
12.
Wang, Michael, Hun Ju Lee, Hubert H. Chuang, et al.. (2015). Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update for a Phase II Clinical Trial. Clinical Lymphoma Myeloma & Leukemia. 15. S65–S65. 4 indexed citations
13.
Cohen, Lorenzo, Ying Guo, Yuhong Zhou, et al.. (2014). Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. Journal of Hematology & Oncology. 7(1). 41–41. 47 indexed citations
14.
15.
Wang, Michael, Fredrick Hagemeister, Jason R. Westin, et al.. (2014). Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood. 124(21). 627–627. 17 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reiko Seki Breakdown of academic impact, for papers by Namrata Shah Breakdown of academic impact, for papers by Sang T. Kim Breakdown of academic impact, for papers by Outi Varpuluoma Breakdown of academic impact, for papers by Federica De Marco Breakdown of academic impact, for papers by Donne Bennett Caces Breakdown of academic impact, for papers by Hui Xiong Breakdown of academic impact, for papers by Yue Ren Breakdown of academic impact, for papers by Cristina Bozzao Breakdown of academic impact, for papers by Abderrazak El Yamani
Rankless by CCL
2026